Turn Therapeutics' Dermatitis Formula Inhibits Key Cytokines in Study

Turn Therapeutics, a pharmaceutical and medical device company focused on immunology, advanced wound care, and dermatology, has announced promising results from a biomarker study of their candidate GX-03. The study aimed to measure the immunological inhibitory effects of GX-03 during eczema induction. Conducted using an eczema model with C57BL/6 mice and a well-established NIH pre-treatment protocol, the study revealed significant findings after a four-day pre-treatment period followed by a three-day disease induction phase.

The key focus was on cytokine levels and average disease severity scores, assessed using the Investigator’s Static Global Assessment (ISGA) scale. GX-03 demonstrated inhibition of critical cytokines involved in various dermatological conditions, including atopic dermatitis. Notably, IL-31 levels, which play a significant role in eczema and atopic dermatitis pathogenesis, were reduced by 67.7% compared to placebo. Similarly, IL-36α and IL-36γ levels were significantly inhibited, showing reductions of 50% and 49%, respectively. IL-36α is a significant cytokine in a range of dermatological issues, while IL-36γ is mainly associated with various forms of psoriasis.

The ISGA is a 5-point rating scale recommended by the US Food and Drug Administration to assess the severity of atopic dermatitis. The success measured by ISGA is a common endpoint in clinical studies for atopic dermatitis. With the pre-treatment regimen of GX-03, there was a significant reduction in the ISGA score to 0.83, indicating clear to almost clear skin, compared to a score of 2.44 with the placebo, representing mild to moderate eczema.

Bradley Burnam, founder and CEO of Turn Therapeutics, emphasized the significance of these results, particularly because they were achieved through pre-treatment before disease induction. This suggests that GX-03 has powerful dermal penetration and lasting effects. Burnam expressed optimism about the potential efficacy of GX-03 in treating eczema, highlighting its non-steroid, non-injectable nature, and its extensive safety history in human use.

The study's results were recently featured in Dermatology Times. GX-03's formulation has a well-documented safety profile and has received FDA clearance for other indications, confirming its non-cytotoxicity and lack of sensitization potential.

Turn Therapeutics plans to leverage these findings for future clinical applications. The company projects that phase 1b/2 efficacy trials will commence in 2025. This aligns with their broader goal of offering new, safe, and effective treatment options for conditions such as eczema and onychomycosis.

Turn Therapeutics continues to focus on advanced wound and dermatologic care, targeting broad indications where few safe or effective options currently exist. Their innovative flagship formula shows remarkable efficacy for various conditions, driven by data and guidance from medical experts.

In summary, Turn Therapeutics' GX-03 has shown significant promise in reducing key cytokines and improving ISGA scores in eczema models. The company is poised to advance into clinical trials, aiming to provide a novel, non-steroidal treatment option for eczema sufferers.